May 27 2026 – Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today announced that it registered certain state-licensed medical cannabis facilities with the U.S. Drug Enforcement Administration (“DEA”) following the federal rescheduling of medical cannabis to Schedule III under the Controlled Substances Act. The registrations are related to dispensary, cultivation and processing operations serving medical cannabis patients in the Company’s footprint.
“Registering our medical cannabis operations with the DEA marks a significant milestone for Cresco Labs and for the continued evolution of the cannabis industry,” said Charlie Bachtell, CEO of Cresco Labs. “For the first time, the work we do is federally recognized—advancing normalization, reducing uncertainty, and reinforcing safe, responsible access to medicine for patients across the country.”
The expedited 60-day DEA registration pathway was established following the federal government’s rescheduling of medical marijuana to Schedule III, which created a mechanism for eligible state-licensed medical cannabis operators to register certain activities with the DEA.
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated January 29, 2026, to its short form base shelf prospectus dated October 3, 2025.
About Cresco Labs Inc.
Cresco Labs’ mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production, and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s, and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development, and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible.
